MapLight Therapeutics Inc. Common Stock (MPLT)
Stock · NASDAQ · Health Care
$7.7as of 10/16/2026
Price chart
Active signals
Resistance level
$27.96
Industry
Biotechnology: Pharmaceutical Preparations
About MPLT
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spe…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 133
- Website
- maplightrx.com/
Fundamentals
- 1-day range
- $7.94$8.6
- Market cap
- $602.19M
- P/E (trailing)
- —
- P/E (forward)
- -2.33
- EPS (trailing)
- $-12.54
- Dividend yield
- —
- Beta
- 0.80
- Avg. volume
- 840.5K
52-week range
$8.7$40.43
Next earnings: November 12, 2026 · EPS estimate $-1.17confirmed
Forecasts
13 analyst ratings
Buy 85%
Hold 15%
Sell 0%
1-year price forecast
High
$43
+458.4%
Median
$25
+224.7%
Low
$13
+68.8%
MapLight Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MPLTMapLight Therapeutics Inc. Common Stock$7.7▼ 3.99%Market cap $602.19MP/E —$8.7$40.43
- CBIOCrescent Biopharma Inc. Common Stock$11.84▼ 5.13%Market cap $610.27MP/E —$8.72$27.41
- NVCTNuvectis Pharma Inc. Common Stock$18.6▼ 1.74%Market cap $613.51MP/E —$5.55$29.28
- CRMDCorMedix Inc. Common Stock$7.26▼ 2.68%Market cap $589.17MP/E 3.08$6.13$13.02
- ALTAltimmune Inc. Common Stock$2.2▼ 6.78%Market cap $585.37MP/E —$2.56$6.44
- CTNMContineum Therapeutics Inc. Class A Common Stock$7.08▼ 10.38%Market cap $577.48MP/E —$7.96$17.79
- FTHFaeth Therapeutics Inc. Common Stock$18.8▼ 8.74%Market cap $632.57MP/E —$13.43$42.14
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MPLT MapLight Therapeutics Inc. Common Stock | $602.19M | — | $7.7 | ▼ 3.99% | $8.7$40.43 |
| CBIO Crescent Biopharma Inc. Common Stock | $610.27M | — | $11.84 | ▼ 5.13% | $8.72$27.41 |
| NVCT Nuvectis Pharma Inc. Common Stock | $613.51M | — | $18.6 | ▼ 1.74% | $5.55$29.28 |
| CRMD CorMedix Inc. Common Stock | $589.17M | 3.08 | $7.26 | ▼ 2.68% | $6.13$13.02 |
| ALT Altimmune Inc. Common Stock | $585.37M | — | $2.2 | ▼ 6.78% | $2.56$6.44 |
| CTNM Contineum Therapeutics Inc. Class A Common Stock | $577.48M | — | $7.08 | ▼ 10.38% | $7.96$17.79 |
| FTH Faeth Therapeutics Inc. Common Stock | $632.57M | — | $18.8 | ▼ 8.74% | $13.43$42.14 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →Acquired
1.22M
Disposed
80.8K
- Lillie James Woodruff · August 3, 2026 · Sale22.1K @ $12.54
- Catalyst4, Inc. · July 30, 2026 · Buy1.00M @ $13
- Catalyst4, Inc. · July 29, 2026 · Buy3.0K @ $12.63
- Catalyst4, Inc. · July 28, 2026 · Buy65.1K @ $11.69
- Catalyst4, Inc. · July 28, 2026 · Buy141.1K @ $10.74
- Troy Cox · July 28, 2026 · Buy15.6K @ $9.52
- Foff Erin Pennock · July 17, 2026 · Sale3.7K @ $37.9
- Hanson Kristopher · July 17, 2026 · Sale1.1K @ $37.9
- Lillie James Woodruff · July 17, 2026 · Sale2.1K @ $37.9
- Kroeger Christopher A. · July 17, 2026 · Sale16.8K @ $37.9
- Kreitzer Anatol · July 17, 2026 · Sale200 @ $38.39
- Kreitzer Anatol · July 17, 2026 · Sale14.1K @ $37.7
- Kreitzer Anatol · July 17, 2026 · Sale2.8K @ $37.05
- GILLIS JONATHAN · July 17, 2026 · Sale900 @ $38.17
- GILLIS JONATHAN · July 17, 2026 · Sale17.0K @ $37.61
Institutional Ownership
March 31, 2026
- Total shares held
- 24.44M
- Total value held
- $437.68M
- Institutional holders
- 77
Top holders this quarter
- Unknown3.69M
- Unknown3.23M
- Unknown2.80M
- Unknown1.99M
- Unknown1.34M
- Unknown1.01M
- Unknown971.3K
- Unknown950.0K
- Unknown912.0K
- Unknown719.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MapLight Therapeutics Shares Fall 34.8% in Four Weeks
MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.
MapLight Therapeutics Shares Fall 34.8% in Four Weeks. MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.